https://scholars.lib.ntu.edu.tw/handle/123456789/476327
標題: | Intracystic interferon-alpha in pediatric craniopharyngioma patients: An international multicenter assessment on behalf of SIOPE and ISPN | 作者: | Kilday J.-P. Caldarelli M. Massimi L. Chen R.H.-H. Lee Y.Y. Liang M.-L. Parkes J. Naiker T. Van Veelen M.-L. Michiels E. Mallucci C. Pettorini B. Meijer L. Dorfer C. Czech T. Diezi M. Schouten-Van Meeteren A.Y. Holm S. Gustavsson B. Benesch M. M?ller H.L. Hoffmann A. Rutkowski S. Flitsch J. Escherich G. Grotzer M. Spoudeas H.A. Azquikina K. Capra M. JimCrossed S.G.R. Mac Donald P. Johnston D.L. Dvir R. Constantini S. MENG-FAI KUO SHIH-HUNG YANG Bartels U. |
公開日期: | 2017 | 出版社: | Oxford University Press | 卷: | 19 | 期: | 10 | 起(迄)頁: | 1398-1407 | 來源出版物: | Neuro-Oncology | 摘要: | Background: Craniopharyngiomas are frequent hypothalamo-pituitary tumors in children, presenting predominantly as cystic lesions. Morbidity from conventional treatment has focused attention on intracystic drug delivery, hypothesized to cause fewer clinical consequences. However, the efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centers using intracystic interferon-alpha. Methods: European Soci?t? Internationale d'Oncologie P?diatrique and International Society for Pediatric Neurosurgery centers were contacted to submit a datasheet capturing pediatric patients with cystic craniopharyngiomas who had received intracystic interferon-alpha. Patient demographics, administration schedules, adverse events, and outcomes were obtained. Progression was clinical or radiological (cyst reaccumulation, novel cysts, or solid growth). Results: Fifty-six children (median age, 6.3 y) from 21 international centers were identified. Median follow-up from diagnosis was 5.1 years (0.3-17.7 y). Lesions were cystic (n = 22; 39%) or cystic/solid (n = 34; 61%). Previous progression was treated in 43 (77%) patients before interferon use. In such cases, further progression was delayed by intracystic interferon compared with the preceding therapy for cystic lesions (P = 0.0005). Few significant attributable side effects were reported. Progression post interferon occurred in 42 patients (median 14 mo; 0-8 y), while the estimated median time to definitive therapy post interferon was 5.8 (1.8-9.7) years. Conclusions: Intracystic interferon-alpha can delay disease progression and potentially offer a protracted time to definitive surgery or radiotherapy in pediatric cystic craniopharyngioma, yet demonstrates a favorable toxicity profile compared with other therapeutic modalities-important factors for this developing age group. A prospective, randomized international clinical trial assessment is warranted. ? 2017 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030755330&doi=10.1093%2fneuonc%2fnox056&partnerID=40&md5=16aac3130d26adb30223c25a66bc55a0 https://scholars.lib.ntu.edu.tw/handle/123456789/476327 |
ISSN: | 1522-8517 | DOI: | 10.1093/neuonc/nox056 | SDG/關鍵字: | alpha interferon; radioisotope; steroid; alpha interferon; acute disease; adolescent; Article; brain atrophy; brain edema; cancer control; child; clinical evaluation; clinical outcome; cohort analysis; conformal radiotherapy; confusion; controlled study; craniopharyngioma; demography; disease exacerbation; drug efficacy; drug safety; endocrine surgery; fatigue; female; gamma knife radiosurgery; headache; human; human tissue; hydrocephalus; hypernatremia; hyponatremia; incontinence; influenza; international cooperation; loss of appetite; major clinical study; malaise; male; medical society; multicenter study (topic); multiple cycle treatment; neurosurgery; preschool child; proton therapy; radiodiagnosis; retrospective study; school child; side effect; treatment response; tumor growth; visual disorder; weight reduction; clinical trial; craniopharyngioma; hypophysis tumor; intralesional drug administration; metabolism; multicenter study; procedures; Adolescent; Child; Child, Preschool; Craniopharyngioma; Female; Humans; Injections, Intralesional; Interferon-alpha; Male; Pituitary Neoplasms; Retrospective Studies |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。